logo
More Pregnancies With Weight Loss Before IVF

More Pregnancies With Weight Loss Before IVF

Medscape2 days ago
Women with obesity who lost weight prior to in vitro fertilization (IVF) had increased pregnancy rates, especially unassisted conceptions, a systematic review and meta-analysis has found.
The studies reviewed were small and heterogeneous, making it difficult to determine which weight loss interventions had the most efficacy, according to the authors. Still, they concluded that weight loss in this cohort might 'negate the need for treatment, and does not seem to increase the risk for pregnancy loss, although evidence on the effect on live births was unclear.'
The results were published online August 12 in the Annals of Internal Medicine.
Obesity is associated with ovulatory dysfunction, reduced ovarian responsiveness to agents that induce ovulation, altered oocyte and endometrial function, and lower birth rates after IVF, according to an opinion published by the Practice Committee of the American Society for Reproductive Medicine in 2021.
Previously, it was unknown whether weight loss before IVF improves reproductive outcomes, so Moscho Michalopoulou, MSc, DPhil, a behavioral scientist at Oxford University in the United Kingdom, and a team of researchers reviewed 12 randomized controlled studies (RCTs) of 1921 women with obesity who were offered a weight loss intervention before planned IVF.
The studies included in the analysis were of women in upper-middle or high-income countries who had a median body mass index of 33.6 kg/m2. They were typically in their early 30s, and their weight loss prior to conception tended to be modest across the studies included. Nearly a quarter of women from nine studies had polycystic ovary syndrome. Weight loss in this PCOS population was associated with fewer unassisted conceptions.
There were numerous weight loss interventions across the RCTs, and their median duration of an active weight loss phase was 12 weeks (range 5 - 24 weeks).
Controls across the studies in the analysis received usual care, yet in six studies they received no or minimal intervention. In the remaining six studies, usual care was a less intense weight loss intervention than in the study arm. Participants across all intervention groups lost 4 kg more than controls, the researchers found.
The difference in weight change between groups was larger when interventions were compared with no or minimal intervention rather than to an active control. The average follow-up for reproductive outcomes was 9.3 months (range 1.3 - 18 months) for intervention groups vs 11.2 months (range 4.3 - 24 months) for controls.
Ten studies reported unassisted pregnancy rates (1466 participants). Eight studies favored intervention; however, most studies had few unassisted pregnancies, resulting in wide confidence intervals.
Overall, the investigators found that weight loss interventions before IVF were associated with greater unassisted pregnancy rates (relative risk, 1.47; 95% CI, 1.26 - 1.73). The effect size was greater in the RCTs with controls involving no or minimal intervention vs an active weight loss comparator, although the small number of studies and events limited formal comparison.
No consistent pattern was observed when studies were sorted by the difference in weight change between groups, age, or baseline BMI, but the study authors found a tendency for fewer unassisted pregnancies with an increasing proportion of women with PCOS in the sample.
'There was inconclusive evidence on the effect of weight loss interventions on treatment-induced pregnancies. Overall, evidence on the association between weight loss interventions before IVF and live births was uncertain, although there was moderate certainty of no association with pregnancy loss,' the investigators write.
The authors noted that a weakness in their study was a lack of follow-up on pregnancy outcomes. 'Unfortunately, fewer studies reported live birth outcomes, not all studies followed up on unassisted conceptions to determine live birth, and evidence on live births was further limited by heterogeneity in study design and clinical characteristics of recruited populations,' the authors write.
Another deficit in the study, according to the authors, was that the studies reviewed had 'marked variability in eligibility and in participant characteristics that affect IVF success and could have influenced the effect of weight loss interventions on outcomes.'
According to an accompanying editorial written by Alan S. Penzias, MD,'[The authors] highlight for future investigators the need for studies that include outcomes, including pregnancy loss and live birth, for both medically assisted and unassisted pregnancies.'
Penzias directs the Fellowship Program in Reproductive Endocrinology and Infertility at the Boston IVF/Beth Israel Deaconess Medical Center, and is an associate professor of Obstetrics, Gynecology and Reproductive Biology at Harvard Medical School, Boston, Massachusetts.
The women in the studies Michalopoulou and her colleagues analyzed tended to be in their early 30s, which Penzias focused on in his editorial. 'A woman's age is the strongest predictor of successfully becoming pregnant,' he writes. 'The association of increasing age with reduced fecundity is so strong that some advocate consideration of IVF as a first-line treatment strategy in women older than 38 to 40 years. It is critical to balance the time it takes to achieve weight loss and the benefit of weight loss on medically unassisted conception.'
Penzias suggested that in addition to a woman's age, her preferred family size, which cannot be determined by weight loss, must also be factored in when deciding whether to use IVF.
'It is important to understand that once an oocyte is retrieved via IVF, any embryo created from its fertilization will always carry the success rate associated with the woman's age at the time of retrieval,' Penzias writes.
For Cate Varney, DO, an associate professor in the Department of Family Medicine at University of Virginia School of Medicine in Charlottesville, the age of the woman seeking to become pregnant does matter, but that 'it is well-established that obesity plays a significant role in infertility. There is a gap in the data between the association and modifiable risk,' she told Medscape Medical News.
'The timing and amount of clinically meaningful weight loss will be important to identify so we can clarify the trade-offs between delaying IVF for weight loss vs age-related fertility decline,' said Varney, who is also the obesity medicine director at UVA Health.
The study was supported by the National Institute for Health and Care Research Applied Research Collaboration Oxford and Thames Valley. The study authors and editorialist Penzias reported no relevant financial relationships. Varney is an advisor and in the speaker's bureau for Eli Lilly.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Pregnant Woman, 29, Thought She Had Morning Sickness. Then, She Was Diagnosed with a Fast-Growing Cancer
Pregnant Woman, 29, Thought She Had Morning Sickness. Then, She Was Diagnosed with a Fast-Growing Cancer

Yahoo

time7 hours ago

  • Yahoo

Pregnant Woman, 29, Thought She Had Morning Sickness. Then, She Was Diagnosed with a Fast-Growing Cancer

"I went from looking at prams and cots to looking at wigs," the woman told SWNS NEED TO KNOW A pregnant woman who thought she had morning sickness was eventually diagnosed with a fast-growing cancer Sophia Yasin, 29, of Middlesbrough, England, said she was experiencing intense nausea, night sweats and itchiness before her diagnosis She said people around her assured her that her symptoms were 'normal' and would subside with time A pregnant woman thought her extreme nausea was simply morning sickness — until she received a life-altering cancer diagnosis. Sophia Yasin, 29, of Middlesbrough, England, became pregnant in June 2024. The housing support worker and her husband had just purchased a home, and they were looking forward to the future ahead, per SWNS. It was around that time when Sophia began experiencing a host of unpleasant symptoms. "I was [vomiting] all day, every few hours. I was getting night sweats and itchiness through the night. I was very uncomfortable,' she told the outlet. Sophia said people around her told her not to worry, reassuring her that this was all 'normal.' "Everyone told me it was very normal in the first trimester and should ease up,' she recalled, adding, 'I did have some worry, but I thought it was normal for my first pregnancy.' However, her situation took a sudden turn when she collapsed at work at the beginning of her second trimester. "I remember seeing black, and I blacked out,' she told SWNS. Sophia was rushed to the local hospital, where doctors initially suspected she had pneumonia. However, scans and a biopsy revealed that she had a tumor over her heart. She was diagnosed with pre-mediastinal large B-cell non-Hodgkin's lymphoma — a type of cancer that affects the lymphatic system — in September 2024. Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer​​, from celebrity news to compelling human interest stories. "I remember saying, 'What does this mean for the baby?' I remember being numb,' Sophia said. The doctors told Sophia that the tumor over her heart was growing fast, and that she needed to begin chemotherapy immediately if she had any chance of survival. However, treatment could also harm or lead to the death of her unborn child. Sophia and her husband ultimately made the difficult decision to terminate the pregnancy based on the many medical variables at hand. While Sophia was devastated by the loss of her pregnancy, she also acknowledged that it may have saved her life. 'Because I was pregnant, I was prioritized [within the health care system]. In a way, because I was pregnant, they found the cancer in time," she told SWNS. Sophia said she was forced to fight for her next chapter while also grieving the loss of what could have been. "I was grieving a baby but trying to have treatment,' she recalled. She added, 'I lost a lot in a short period of time. I went from looking at prams and cots to looking at wigs. I lost my hair, my baby and my old life." Sophia officially went into remission in January 2025 after six rounds of chemotherapy — but she said she has not forgotten the baby she lost — a daughter whom she and her husband named Kainaat Pearl. She told the outlet that she would like to try for a child again, but that doctors have advised her to wait two years, as there is an increased risk of the cancer returning within that window. Sophia has since established a GoFundMe for a fundraising walk to benefit Lymphoma Action, a U.K. charity dedicated to lymphoma. 'Last summer, my world changed forever,' Sophia wrote on the fundraising page. 'In the midst of what should have been one of the happiest times of my life, I faced the unimaginable: fighting for my life while having to say goodbye to my baby girl, Kainaat Pearl.' 'Every step we take is for Kainaat, for those still fighting and for those we've lost,' she added. The GoFundMe has raised $1,356 toward a goal of $1,490. Read the original article on People

Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns
Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns

Yahoo

time7 hours ago

  • Yahoo

Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns

Key Points CRISPR Therapeutics' first approved therapy, Casgevy, was a breakthrough. One of Casgevy's biggest achievements may be demonstrating the viability of CRISPR Therapeutics' strategy. The biotech company could soar if it can follow up that win with more clinical and regulatory milestones. 10 stocks we like better than CRISPR Therapeutics › Over the past few years, the market hasn't been kind to somewhat speculative, unprofitable stocks. CRISPR Therapeutics (NASDAQ: CRSP), a mid-cap biotech, fits that description. The company's shares are down by 24% since mid-2022. The S&P 500 is up 50% over the same period. Despite this terrible performance, there are reasons to believe that CRISPR Therapeutics could still generate life-changing returns for investors willing to be patient. Here's how the biotech could pull it off. CRISPR Therapeutics' first success CRISPR Therapeutics' first approval was for Casgevy, a treatment for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), which it developed in collaboration with Vertex Pharmaceuticals. Before Casgevy, no CRISPR-based gene-editing medicine had been approved. While it became the first, it still faces some challenges. Ex vivo gene-editing therapies require a complex manufacturing and administration process that can only be performed in authorized treatment centers (ATCs). Moreover, they're expensive. Casgevy costs $2.2 million in the U.S. Getting third-party payers on board for that is no easy feat. Still, CRISPR Therapeutics and Vertex Pharmaceuticals are making steady progress. As of the second quarter, CRISPR Therapeutics had achieved its goal of activating 75 ATCs. It had also secured reimbursement for eligible patients in 10 countries. The two companies estimate there are roughly 60,000 eligible SCD and TDT patients in the regions they have targeted. Let's say they continue to strike reimbursement deals and can count on third-party coverage for 70% of this target population (42,000 people), then go on to treat another 30% of that group in the next decade (12,600 patients). Assuming they could extend that $2.2 million price tag to those countries, Casgevy could generate more than $27.7 billion over this period. Based on its agreement with Vertex, 40% would go to CRISPR Therapeutics, or roughly $11.1 billion over a decade. That's not bad, but it's not that impressive either. So, while Casgevy could contribute meaningfully to CRISPR Therapeutics' results -- and may even reach blockbuster status at some point -- the medicine may primarily serve as a proof of concept to demonstrate that the biotech's approach can be effective. Substantial progress with its first commercialized product will help the stock price. But the company's performance will depend even more on future clinical and regulatory milestones, especially as it shows with Casgevy that it can manage the intricacies and complexities of marketing gene-editing medicines. Can the pipeline deliver? CRISPR Therapeutics has six candidates in clinical trials, which isn't bad at all for a mid-cap biotech company. One of its leading programs is CTX310, a potential therapy designed to help reduce low-density lipoprotein (LDL) cholesterol in patients with certain conditions. CTX310 is already producing encouraging clinical trial results. Additionally, it's an in vivo medicine, meaning it bypasses the need to harvest patients' cells to manufacture therapies; in vivo gene-editing treatments are easier to handle than their ex vivo counterparts. The company's path to creating life-changing returns hinges on its ability to deliver consistent clinical and regulatory wins over the next few years for CTX310 and other important candidates. If CRISPR Therapeutics can successfully launch several new products in the next five to seven years, its shares are likely to skyrocket. In the meantime, under this scenario, the company would succeed in making gene-editing medicines more mainstream. This would encourage third-party payers to get on board -- and healthcare institutions, and perhaps even governments, to help push for more ATCs, since there'd be a greater need to accommodate these treatments. Can CRISPR Therapeutics achieve this? In my view, the biotech stock is on the riskier side, but does carry significant upside potential. There's a (small) chance the gene-editing specialist will deliver life-changing returns in the next decade, but investors need to hedge their bets. It's best to start by initiating a small position in the stock, then progressively add more if CRISPR Therapeutics lands more wins. Should you invest $1,000 in CRISPR Therapeutics right now? Before you buy stock in CRISPR Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CRISPR Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns was originally published by The Motley Fool

It's been a long road, but Blood Oxygen tracking is back for the newest Apple Watches in the US – but the feature isn't the same
It's been a long road, but Blood Oxygen tracking is back for the newest Apple Watches in the US – but the feature isn't the same

Yahoo

time8 hours ago

  • Yahoo

It's been a long road, but Blood Oxygen tracking is back for the newest Apple Watches in the US – but the feature isn't the same

When you buy through links on our articles, Future and its syndication partners may earn a commission. Following an 18-month ban, Blood Oxygen tracking is coming back to the Apple Watch Series 9, Series 10, and Ultra 2 It's not an entirely on-device experience anymore, though The Apple Watch still measures Blood Oxygen, but the iPhone will calculate and display the final result It's been a long 18 months, but Apple's announced that Blood Oxygen tracking and monitoring are returning to the Apple Watch Series 9, Series 10, and Ultra 2 in the United States. The feature was disabled and effectively banned on the Series 9 and Ultra 2 – then the Series 10, which launched later – after a ruling in January 2024 due to a patent dispute over the technology being used between Massimo and Apple. Now, thanks to iOS 18.6.1 and watchOS 11.6.1, which will roll out later today, the feature is returning in a 'redesigned' form. In its new iteration, the Apple Watch Series 9, Series 10, and Ultra 2's sensors can take a reading, then transmit the data to the connected iPhone, where it will be calculated and displayed in the Health app under 'Respiratory' readings. So no, you won't be able to take the reading, watch as it progresses, and then view the results right on your wrist, as you could before. Still, this does effectively return the tracking and monitoring functionality to the impacted Apple Watch models in the United States. In a statement shared, Apple explains the changes as: 'Users with these models in the U.S. who currently do not have the Blood Oxygen feature will have access to the redesigned Blood Oxygen feature by updating their paired iPhone to iOS 18.6.1, and their Apple Watch to watchOS 11.6.1. Following this update, sensor data from the Blood Oxygen app on Apple Watch will be measured and calculated on the paired iPhone, and results can be viewed in the Respiratory section of the Health app. This update was enabled by a recent U.S. Customs ruling.' The U.S. Customs ruling is key here, as this will return the feature to the Apple Watches sold when the ban began and was subsequently enforced. If you still have an older Apple Watch, or one sold prior to January 2024, the Blood Oxygen functionality remains unimpacted and won't be changed. That also goes for any models sold outside of the United States, which have been unimpacted by this ruling. Still, this does return the Blood Oxygen feature to the Apple Watch, even if it splits the experience between watch and phone. But this separation is likely key to having this allowed and approved by U.S. Customs. For those who have purchased an Apple Watch Series 9, 10, or Ultra 2 in those many months, this is a return to form and rounding out of the health tracking features on Apple's star wearable in the United States. Even in our Apple Watch Series 10 review, we noted that the Blood Oxygen tracking feature was missing in the US. Apple has a pretty smart rollout here, and considering rumors of further pushes into health features that we might see with future generations of Apple Watch models, it might be helpful to have these readings going straight into the Health app. Either route, though, if you've been waiting for Blood Oxygen tracking to return, it's back, but you'll want to make sure your iPhone is nearby if you want to see the results. While Apple has not shared an exact timing for the rollouts of iOS 18.6.1 and watchOS 11.6.1, it has promised to arrive today – August 14, 2025 – in the United States, and we'll update this piece when we see it rolling out. You might also like Constantly dismissing notifications on your Apple Watch? You're going to love Apple's watchOS 26 latest gesture I'm a fitness tracker expert, and here are my top 3 subscription-free picks for 2025 Garmin Venu X1 review: The most innovative Garmin watch in years, and a genuine Apple Watch Ultra rival

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store